Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 6/20 | 0.64 |
| ▸ | ALB | P02768 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25311559 | 0.90 | TTR (0.77) | TTRALBSMN1; SMN2HSD17B10MAPT | |
| SCHEMBL24953188 | 0.87 | TTR (0.83) | TTRALBSMN1; SMN2HSD17B10MAPT | |
| SCHEMBL26740155 | 0.84 | TTR (0.65) | TTRALBSMN1; SMN2HSD17B10MAPT | |
| SCHEMBL17522783 | 0.84 | TTR (0.81) | TTRALBSMN1; SMN2HSD17B10MAPT | |
| SCHEMBL26746919 | 0.82 | TTR (0.48) | TTRALBSMN1; SMN2HSD17B10MAPT | |
| SCHEMBL26740133 | 0.80 | TTR (0.59) | TTRALBSMN1; SMN2HSD17B10MAPT | |
| Acoramidis SCHEMBL29350324 | 0.78 | TTR (1.00) | TTRALBSMN1; SMN2HSD17B10MAPT | |
| SCHEMBL17522792 | 0.78 | TTR (0.69) | TTRALBSMN1; SMN2HSD17B10MAPT | |
| Acoramidis SCHEMBL15816954 | 0.78 | TTR (1.00) | TTRALBSMN1; SMN2HSD17B10MAPT | |
| Acoramidis SCHEMBL29390976 | 0.77 | TTR (0.98) | TTRALBSMN1; SMN2HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | TTR, C1R, APOB | TTR 1/4885ALB 6/4885SMN1; SMN2 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.